Active	Status	Sponsor type	Region	Phase	Filter
19 Active 8 Inactive 27 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ciceri, Fabio
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
ARES, NCT04769895 / 2021-001841-11: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients	Active, not recruiting	3	66	Europe	MaaT013	MaaT Pharma, MaaT Pharma	Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD	11/24	11/25
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Recruiting	3	322	Europe, Canada, US	Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF	Arog Pharmaceuticals, Inc.	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	10/24	10/24
ReSET-02, NCT05768035 / 2022-002530-14: Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide	Recruiting	1/2	40	Europe	Allogeneic T cell progenitors, cultured ex-vivo, SMART101	Smart Immune SAS, SMART IMMUNE	Hematological Malignancies	07/25	07/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ciceri, Fabio
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020 Initiation of new trial in Ph+ ALL Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone	Takeda	Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	08/22	07/27
ARES, NCT04769895 / 2021-001841-11: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients	Active, not recruiting	3	66	Europe	MaaT013	MaaT Pharma, MaaT Pharma	Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD	11/24	11/25
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML	Recruiting	3	322	Europe, Canada, US	Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF	Arog Pharmaceuticals, Inc.	Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations	10/24	10/24
ReSET-02, NCT05768035 / 2022-002530-14: Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide	Recruiting	1/2	40	Europe	Allogeneic T cell progenitors, cultured ex-vivo, SMART101	Smart Immune SAS, SMART IMMUNE	Hematological Malignancies	07/25	07/26